Immune Response News and Research

RSS

COVID-19 is not characterized by a cytokine storm, shows study

Does the COVID-19 cytokine storm exist? Inflammatory proteins, also known as cytokines, play a crucial role in the immune response. If this immune response is too strong, a phenomenon known as "cytokine storm", it can cause harm to the patient.

5 Sep 2020

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.

5 Sep 2020

Study: Small neutralizing antibody can block SARS-CoV-2 from entering human cells

Researchers at Karolinska Institutet in Sweden have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells.

4 Sep 2020

Spike-based priming leads to high neutralizing activity in animal models

A new report by researchers at the University of Melbourne and published on the preprint server bioRxiv in September 2020 reports on the use of a two-protein two-dose vaccine regimen and its immunogenicity in two animal models.

4 Sep 2020

D614G spike mutation increases infectivity of SARS-CoV-2 and neutralization susceptibility

As the COVID-19 pandemic progresses, it is crucial to track the viral changes in order to link the clinical and epidemiological features of the disease with these mutations. A new study published on the preprint server bioRxiv* in September 2020 reports on a common severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation, D614G, and its effects on the virus.

4 Sep 2020

Researchers identify biomarkers associated with bacterial infection mortality

David Gonzalez's "a-ha" moment came when a physician-colleague, George Sakoulas, MD, shared with him one of the biggest problems faced in clinical practice: How long it takes to diagnose a patient.

4 Sep 2020

CRISPR-based system suppresses genes related to AAV antibody production

Gene therapy generally relies on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In the case of CRISPR-based gene therapies, molecular scissors can then snip out a defective gene, add in a missing sequence or enact a temporary change in its expression, but the body's immune response to AAV can thwart the whole endeavor.

4 Sep 2020

Research compares T cell responses to SARS-CoV-2 and influenza

As the COVID-19 pandemic continues to grow, scientists are focusing on understanding how the host immune system responds to the virus in order to better shape public health responses and develop effective vaccines. A new study published on the preprint server medRxiv in September 2020 reports the T cell memory response to the SARS-CoV-2 spike protein, recombinant nucleocapsid protein, and other pooled peptides derived from convalescent patients.

3 Sep 2020

Underlying pathology of MIS-C in children following SARS-CoV-2 infection

Researchers at the Icahn School of Medicine at Mount Sinai, New York, have conducted a study that sheds light on the molecular underpinnings of multisystem inflammatory syndrome in children (MIS-C).

3 Sep 2020

COVID-19 vaccine candidate protects animals against SARS-CoV-2

Most people with COVID-19 have relatively mild disease, but a subset of people develop severe pneumonia and respiratory failure, potentially leading to death.

3 Sep 2020

Improving COVID-19 diagnosis

News-Medical spoke to Yourgene health on their efforts during the COVID-19 pandemic, and how they developed a diagnostic test for COVID-19.

From Yourgene Health 3 Sep 2020

Relation Therapeutics announces Project RE to identify COVID-19 therapeutic candidates

Relation Therapeutics, a drug development company driven by data science and machine learning, today announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.

3 Sep 2020

Reformulated generic drug could offer a cost-effective way to accelerate recovery, prevent hospitalizations

Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations.

3 Sep 2020

Bioengineering technique that boosts protein production could lead to effective COVID-19 vaccine

A bioengineering technique to boost production of specific proteins could be the basis of an effective vaccine against the novel coronavirus that causes COVID-19, new research suggests.

3 Sep 2020

Researchers identify properties in placenta tissue that may prevent COVID-19 transmission

Researchers from Boston Medical Center's Maxwell Finland Laboratory for Infectious Diseases have identified properties in placenta tissue that may play an important role in preventing the transmission of COVID-19 from a mother with the virus to her fetus.

3 Sep 2020

Antibody responses in recovered COVID-19 individuals from India

India has been hit hard by COVID-19, with at least 66,000 deaths and almost 4 million cases. The need to understand the infection, including the various antibody isotypes, and whether neutralizing antibodies and memory B cells are being produced, has driven much research into the way immunity is developing in Indian patients.

3 Sep 2020

UC San Diego participates in second, massive clinical trial of COVID-19 vaccine

UC San Diego Health will be part of a second, massive clinical trial to assess the safety, efficacy and immunogenicity of a vaccine designed to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19.

2 Sep 2020

Study provides direct link between inflammation and Alzheimer’s plaque development

Alzheimer's disease is a neurodegenerative condition that is characterized by the buildup of clumps of beta-amyloid protein in the brain.

2 Sep 2020

Durable IgG antibodies to SARS-CoV-2 from the Iceland experience

Now, a team of scientists at the Reykjavik-based deCODe Genetics, a subsidiary of the U.S. biotech company Amgen, and several universities and hospitals in Iceland, says that the antibodies developed to fight SARS-CoV-2 last for at least four months and do not fade quickly as previously thought.

2 Sep 2020

A global vaccine is sufficient to combat COVID-19 infection, indicates study

Genetic analysis of sequences from more than 27,000 individuals infected with the coronavirus that causes COVID-19 reveals that the virus has mutated minimally since December 2019, suggesting one vaccine would be sufficient to combat global infections.

2 Sep 2020

Immune Response News and Research

COVID-19 is not characterized by a cytokine storm, shows study

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Study: Small neutralizing antibody can block SARS-CoV-2 from entering human cells

Spike-based priming leads to high neutralizing activity in animal models

D614G spike mutation increases infectivity of SARS-CoV-2 and neutralization susceptibility

Researchers identify biomarkers associated with bacterial infection mortality

CRISPR-based system suppresses genes related to AAV antibody production

Research compares T cell responses to SARS-CoV-2 and influenza

Underlying pathology of MIS-C in children following SARS-CoV-2 infection

COVID-19 vaccine candidate protects animals against SARS-CoV-2

Improving COVID-19 diagnosis

Relation Therapeutics announces Project RE to identify COVID-19 therapeutic candidates

Reformulated generic drug could offer a cost-effective way to accelerate recovery, prevent hospitalizations

Bioengineering technique that boosts protein production could lead to effective COVID-19 vaccine

Researchers identify properties in placenta tissue that may prevent COVID-19 transmission

Antibody responses in recovered COVID-19 individuals from India

UC San Diego participates in second, massive clinical trial of COVID-19 vaccine

Study provides direct link between inflammation and Alzheimer’s plaque development

Durable IgG antibodies to SARS-CoV-2 from the Iceland experience

A global vaccine is sufficient to combat COVID-19 infection, indicates study

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News